Target intelligence / Profile preview

Integrin alpha-5 beta-1 receptor\nIntegrin alpha-V beta-3 receptor\nIntegrin alpha-V beta-5 receptor (Integrin α5β1\nIntegrin αvβ3\nIntegrin αvβ5)

Target
Integrin α5β1\nIntegrin αvβ3\nIntegrin αvβ5
Molecular classification
Receptor, Adhesion receptor, Integrin family, Heterodimeric transmembrane protein
01

Overview

Integrin alpha-5 beta-1 (α5β1), alpha-V beta-3 (αvβ3), and alpha-V beta-5 (αvβ5) are heterodimeric, transmembrane cell surface receptors that mediate cell adhesion to extracellular matrix proteins. α5β1 is the primary fibronectin receptor and plays a fundamental role in cell migration, adhesion, and cytoskeletal organization. αvβ3 and αvβ5 are vitronectin receptors, contributing to cell adhesion, migration, and angiogenesis, and are differentially expressed/distributed on the cell surface. All three integrins participate in "outside-in" and "inside-out" signaling, regulating crucial cellular processes. Their dysregulation has been implicated in cancer, inflammation, fibrosis, and other diseases, making them therapeutic targets for antibody, peptide, and small-molecule inhibitors.

Other names
α5β1 integrinαvβ3 integrinαvβ5 integrinFibronectin receptor (primarily α5β1)Vitronectin receptor (primarily αvβ3, αvβ5)
02

Mechanism of action

Inhibition of ligand binding (e.g., RGD sequence in fibronectin or vitronectin is blocked); Disruption of cell-ECM interaction; Inhibition of angiogenesis (blocking endothelial cell attachment/migration); Induction of apoptosis via loss of matrix attachment (anoikis)

03

Biological functions

Cell adhesionSignal transductionCell migrationCytoskeletal organizationAngiogenesisTissue morphogenesisCell proliferationCell survival
04

Disease associations

Cancer (tumor progression, metastasis, angiogenesis)InflammationCardiovascular diseaseFibrosisInfection (some pathogens exploit integrins for entry)Diabetes/Islet biology (αvβ3 and αvβ5)
05

Safety considerations

Potential for bleeding (due to anti-adhesive/anti-platelet effects)Poor efficacy in late-stage cancer (seen in some clinical trial failures, e.g., cilengitide)Effects on normal tissue remodeling and immune function
06

Interacting drugs

Cilengitide (αvβ3, αvβ5 inhibitor; cancer trials)

2 more in the full profile.

07

Biomarkers

Expression of α5β1, αvβ3, αvβ5 in tumors or inflamed tissues (biomarker for prognosis and response to therapy)Fibronectin and vitronectin deposition/localization

Beyond the preview

Go deeper on Integrin alpha-5 beta-1 receptor\nIntegrin alpha-V beta-3 receptor\nIntegrin alpha-V beta-5 receptor (Integrin α5β1\nIntegrin αvβ3\nIntegrin αvβ5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Integrin alpha-5 beta-1 receptor\nIntegrin alpha-V beta-3 receptor\nIntegrin alpha-V beta-5 receptor (Integrin α5β1\nIntegrin αvβ3\nIntegrin αvβ5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call